Tremfya (guselkumab) approved for reimbursement in Ireland for active psoriatic arthritis

Irish Medical Times

11 November 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson have announced that Tremfya (guselkumab), a first-in-class treatment for adult patients with active psoriatic arthritis who have had an inadequate response or who have been intolerant to a prior disease-modifying anti-rheumatic drug therapy has been granted reimbursement in Ireland.

It is already approved for the treatment of patients with moderate to severe plaque psoriasis.

Read Irish Medical Times article

Michael Wonder

Posted by:

Michael Wonder